

America the Beautiful USA 15

**SADMAN, STERNE, KESSLER & GOLDSTEIN**  
1225 Connecticut Avenue, N.W., Suite 300  
Washington, D.C. 20036

Applicant : KENSIL, et al.  
Serial No. : 200,754  
Filed : May 31, 1988  
For : SAPONIN ADJUVANT

0614.0690004

Docket:

Attorney: SLF/PAD

**When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:**

1. Information Disclosure Statement (pages 1-6)
2. Form PTO-1449 (pages 1-6)
3. Copies of references cited on Form PTO-1449 (21)



**SAIDMAN, STERNE, KESSLER & GOLDSTEIN**

ATTORNEYS AT LAW

1225 CONNECTICUT AVENUE  
WASHINGTON, D.C. 20036

(202) 466-0800

CABLE: PRELEX  
TELEX: 248636 SSK

TELEFAX: (202) 833-8716  
GROUPS I, II & III

BALTIMORE  
INNER HARBOR CENTER  
400 EAST PRATT STREET, SUITE 800  
BALTIMORE, MARYLAND 21202  
(301) 659-7570

ROCKVILLE  
25 WEST MIDDLE LANE  
ROCKVILLE, MARYLAND 20850  
(301) 251-8585


WRITER'S DIRECT NUMBER:

PERRY J. SAIDMAN  
ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
HOLLIE L. BAKER  
NEIL D. GERSHON\*  
HENRY N. WIXON\*  
DAVID K.S. CORNWELL  
MICHELLE PETERS\*  
JOHN D. MITCHELL, JR.\*  
SUSAN NEUBERGER WELLEN  
RICHARD M. LUDWIN\*  
PATRICIA A. DONOVAN\*  
JOAN L. DILLON

ABRAHAM BOGORAD  
OF COUNSEL

RAYMOND C. GLENNY  
JEFFREY I. AUERBACH  
TRACY-GENE GRAVELINE  
ROBERT W. ESMOND  
SCOTT M. ALTER  
REGISTERED  
PATENT AGENTS

\*BAR OTHER THAN D.C.



**FILE COPY**

**December 13, 1988**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Re: U.S. Patent Application  
Serial No.: 200,754; filed May 31, 1988  
For: SAPONIN ADJUVANT  
Our Ref: 0614.0690004

Sir:

The following documents are forwarded herewith for appropriate action by the Patent and Trademark Office:


1. Information Disclosure Statement (pages 1-6)
2. Form PTO-1449 (pages 1-6);
3. Copies of references cited on Form PTO-1449 (21);  
and
4. Return post card.

Honorable Commissioner of  
Patents and Trademarks  
December 13, 1988  
Page 2

The Commissioner is hereby authorized to charge any fees that may be required to Deposit Account No. 19-0036. A duplicate copy of this sheet is enclosed.


Respectfully submitted,

SAIDMAN, STERNE, KESSLER & GOLDSTEIN



Samuel L. Fox  
Attorney for Applicant  
30,353

SLF/PAD/hew  
Enclosure



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

CHARLOTTE A. KENSIL et al.

Serial No. 200,754

Filed: May 31, 1988

For: SAPONIN ADJUVANT

:  
:  
: Art Unit:  
:  
: Examiner:  
:  
: Atty Docket No. 0614.069.0004  
:  
:

**INFORMATION DISCLOSURE STATEMENT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of all documents cited herein also accompany this Information Disclosure Statement.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject invention.

**RELEVANCE OF THE DOCUMENTS**

Reference AL, Japanese Patent Application No. 54-132218, October 15, 1979, discloses the separation of ginseng saponins by liquid chromatography using an adsorbent comprising a cross-linked

polymerized gel, e.g., of starch cross-linked with divinyl-sulfone. An English abstract is provided.

Reference AM, Japanese Patent Application No. 61-007286A, January 13, 1986, discloses the isolation of saponins from soybean seeds using column chromatography. An English abstract is provided.

Reference AA, U.S. Patent No. 4,335,113, June 15, 1982, discloses the extraction of saponin from chrysanthellums by high pressure liquid chromatography.

Reference AB, U.S. Patent No. 4,524,067, June 18, 1985, discloses saponins isolated from soybean seeds wherein extracts are purified with high-pressure liquid chromatography.

Document AR1, Dalsgaard, K., referred to on page 3 of the Specification, discloses the partial purification of an aqueous extract of the saponin adjuvant material from the bark of the tree, Quillaja saponaria Molina, by a combination of gel exclusion and ion exchange chromatography. The disclosed preparation which is commercially available under the name "Quil-A," is characterized chemically as a carbohydrate moiety in glycosidic linkage to the triterpenoid quillaic acid. One of the partially purified fractions, separated by a combination of gel exclusion and ion exchange chromatography, exhibited adjuvant activity in foot-and-mouth disease vaccines in guinea pigs and cattle. It was also disclosed that the active fraction in aqueous solution is present in a micellar state above a critical micellar concentration, and that this property of forming micelles creates an aggregation of monomers that are difficult to separate by standard physical-chemical methods.

Document AS1, Higuchi et al., referred to on page 3 of the Specification, discloses the structure of two desacylsaponins isolated from the bark of Quillaja saponaria Molina by weak alkali. The desacylsaponins were identified as quillaic acid 3,28-0-bisglycosides, each containing eight monosaccharides in glycosidic linkage. Neither the purity nor the biological activity of the desacylsaponins is disclosed.

Reference AT1, Higuchi and Komori, referred to on page 3 of the application, discloses that mild alkaline hydrolysis of the triterpenoid saponin mixture obtained from the bark of Quillaja saponaria produces, as two major products, two desacylsaponins (quillaic acid 3, 28-0-bisglycosides), together with less polar compounds (eliminated acyl groups). This reference also discloses the isolation and structure of the eliminated acyl groups that originated from the acyl moieties of Quillaja saponaria. No biological activity was ascribed to the compounds.

Reference AR2, Dalsgaard, K., referred to on page 8 of the application, is a review article discussing the isolation and characterization of the saponin Quil-A and the evaluation of its adjuvant activity, with special reference to the application of the saponin in the vaccination of cattle against foot-and-mouth disease.

Reference AS2, Scott, et al., referred to on page 8 of the application, discloses studies using  $^{125}\text{I}$ -labelled KLH which show that saponins significantly prolong the retention of antigens at a subcutaneous injection site and also increase the amount reaching the spleen. Both phenomenon were associated with inflammatory responses

to saponin and were markedly reduced following abolition of the inflammatory action of the saponin by addition of cholesterol-containing liposomes. Adjuvant activity was not modified by this treatment.

Reference AT2, Higuchi et al., discloses the characterization of a major component of Quillaja saponin, 3,28-O-bisglycoside. The investigators obtained saponin from the bark of Quillaja saponaria Molina and fractionated it by droplet counter current chromatography (DCCC) and reverse-phase chromatography to isolate the major component named QS-III.

Reference AR3, Petermann et al., is an abstract which discloses that inactive anti-rabies cattle vaccine is potentiated by saponin with or without  $Al(OH)_3$ . The potentiation occurred when both the adjuvant and the lyophilized vaccine were injected simultaneously but separately and also when the adjuvant was incorporated into the liquid vaccine before administration.

Reference AS3, Bomford, R., discloses evidence supporting the hypothesis that the adjuvant, as well as the hemolytic activity of saponin, depends on binding to cholesterol in cell membranes.

Reference AT3, Nagasawa et al., discloses the application of high-performance liquid chromatography to the isolation of ginsenoside-Rb<sub>1</sub>-Rb<sub>2</sub>-Rc-Rd-Re-Rg<sub>1</sub> from ginseng saponins.

Reference AR4, Zhou et al., discloses the isolation by means of reverse phase high-performance liquid chromatography of two ginseng saponins, notoginsenosides-R1 and -R2 and the establishment of their structures by <sup>13</sup>C magnetic resonance spectroscopy and mass spectrometry. Two other known saponins ginsenosides-H1 and -RG2, which were

previously isolated from ginseng roots, were also isolated and identified.

Reference AS4, Bomford, R., discloses studies on the cellular site of action of the adjuvant activity of saponin for sheep erythrocytes. The data showed that attachment of the saponin to the antigen is not essential, suggesting that the adjuvant effect, which is T-cell dependent, is exerted on host cells in the draining lymph node.

Reference AT4, Bomford, R., discloses a comparison of the relative adjuvant efficacy of  $Al(OH)_3$  and saponin as related to the immunogenicity of the antigen.

Reference AR5, Morein et al., discloses the use of Quil-A in the development of ISCOMS, structures for antigenic presentation of membrane proteins from enveloped viruses.

Reference AS5, Strobbe et al., cited in the PCT International Search Report for a related application, discloses studies on the adjuvant activity of saponin fractions in foot-and-mouth disease vaccine. The fractionated saponin was saponin purum album from Merck.

Reference AT5, Mostad and Doehl, cited in the PCT International Search Report for a related application, discloses separation and characterization of oleanene-type pentacyclic triterpenes from Gypsophila arrostii by liquid chromatography and mass spectrometry.

Reference AR6, Egerton et al., cited in the PCT International Search Report for a related application, discloses that aluminum precipitated Bacteriodes nodosus vaccines prepared from two antigens with and without the saponin derivative, Quil-A, did not induce



adverse tissue reactions in sheep. Vaccinated, non-infected Merino sheep had higher agglutination antibody titers when the vaccines included Quil-A. Moreover, the recovery rates in vaccinated sheep affected with foot-rot were higher when the vaccines included Quil-A.

Reference AS6, McColm et al., cited in the PCT International Search Report for a related application, discloses a comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse.


REMARKS

This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application are respectfully requested.

Respectfully submitted,

SAIDMAN, STERNE, KESSLER & GOLDSTEIN



Samuel L. Fox  
Attorney for Applicant  
Registration No. 30,353

Date: December 13, 1988

P52-39.WP

FORM PTO-1449

Atty Docket  
0614.0690004Serial No.  
200,754

## INFORMATION DISCLOSURE STATEMENT

Applicant  
KENSIL, et al.Filing Date  
May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date
AB	4,338,113	06/15/82	Combier et al.			
AB	4,524,067	06/18/85	Arichi et al.			
AC		/ /				
AD		/ /				
AE		/ /				
AF		/ /				
AG		/ /				
AH		/ /				
AI		/ /				
AJ		/ /				
AK		/ /				

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-class	Translation
AL	54-132218	10/15/79	JAPAN			Yes
AM	61-007286A	01/13/86	JAPAN			No
AN		/ /				Yes
AO		/ /				No
AP		/ /				Yes
						No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Dalsgaard, K., <u>Archive für die gesamte Virusforschung</u> 44:243-254 (1974)
AS	1	Higuchi et al., <u>Phytochemistry</u> , 26 (1): 229-235 (1987)
AT	1	Higuchi and Komori, <u>Phytochemistry</u> , 26 (8): 2357-2360 (1987)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

Atty Docket

0614.0690004

Serial No.

200,754

INFORMATION DISCLOSURE STATEMENT

Applicant

KENSIL, et al.

Filing Date

May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	_____	___/___/___	_____	_____	_____	_____
	AB	_____	___/___/___	_____	_____	_____	_____
	AC	_____	___/___/___	_____	_____	_____	_____
	AD	_____	___/___/___	_____	_____	_____	_____
	AE	_____	___/___/___	_____	_____	_____	_____
	AF	_____	___/___/___	_____	_____	_____	_____
	AG	_____	___/___/___	_____	_____	_____	_____
	AH	_____	___/___/___	_____	_____	_____	_____
	AI	_____	___/___/___	_____	_____	_____	_____
	AJ	_____	___/___/___	_____	_____	_____	_____
	AK	_____	___/___/___	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Trans-lation
	AL	_____	___/___/___	_____	_____	_____	Yes No
	AM	_____	___/___/___	_____	_____	_____	Yes No
	AN	_____	___/___/___	_____	_____	_____	Yes No
	AO	_____	___/___/___	_____	_____	_____	Yes No
	AP	_____	___/___/___	_____	_____	_____	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Dalsgaard, K., <u>Acta Veterinari Scandinavica</u> (Suppl.) 69:1-40 (1978)
	AS	2	Scott et al., <u>Int. Archs Allergy appl. Immun.</u> 77:409-412 (1985)
	AT	2	Higuchi et al., <u>Phytochemistry</u> 27 (4): 1165-1168 (1988)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

Atty Docket

0614.0690004

Serial No.

200,754

INFORMATION DISCLOSURE STATEMENT

Applicant

KENSIL, et al

Filing Date

May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	_____	___/___/___	_____	_____	_____	_____
	AB	_____	___/___/___	_____	_____	_____	_____
	AC	_____	___/___/___	_____	_____	_____	_____
	AD	_____	___/___/___	_____	_____	_____	_____
	AE	_____	___/___/___	_____	_____	_____	_____
	AF	_____	___/___/___	_____	_____	_____	_____
	AG	_____	___/___/___	_____	_____	_____	_____
	AH	_____	___/___/___	_____	_____	_____	_____
	AI	_____	___/___/___	_____	_____	_____	_____
	AJ	_____	___/___/___	_____	_____	_____	_____
	AK	_____	___/___/___	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Trans-lation
	AL	_____	___/___/___	_____	_____	_____	Yes No
	AM	_____	___/___/___	_____	_____	_____	Yes No
	AN	_____	___/___/___	_____	_____	_____	Yes No
	AO	_____	___/___/___	_____	_____	_____	Yes No
	AP	_____	___/___/___	_____	_____	_____	Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	3	Petermann, H.G. et al., <u>Chemical Abstracts</u> , 72:198, 88330c (1970)
AS	3	Bomford, R., <u>Int. Archs Allergy Appl. Immun.</u> 63:170-177 (1980)
AT	3	Nagasawa et al. <u>Chem. Pharm. Bull.</u> 28(7):2059-2064 (1980)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

Atty Docket

0614.0690004

Serial No.

200,754

INFORMATION DISCLOSURE STATEMENT

Applicant

KENSIL, et al.

Filing Date

May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	_____	____/____/____	_____	_____	_____	_____
	AB	_____	____/____/____	_____	_____	_____	_____
	AC	_____	____/____/____	_____	_____	_____	_____
	AD	_____	____/____/____	_____	_____	_____	_____
	AE	_____	____/____/____	_____	_____	_____	_____
	AF	_____	____/____/____	_____	_____	_____	_____
	AG	_____	____/____/____	_____	_____	_____	_____
	AH	_____	____/____/____	_____	_____	_____	_____
	AI	_____	____/____/____	_____	_____	_____	_____
	AJ	_____	____/____/____	_____	_____	_____	_____
	AK	_____	____/____/____	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Trans-lation
	AL	_____	____/____/____	_____	_____	_____	Yes No
	AM	_____	____/____/____	_____	_____	_____	Yes No
	AN	_____	____/____/____	_____	_____	_____	Yes No
	AO	_____	____/____/____	_____	_____	_____	Yes No
	AP	_____	____/____/____	_____	_____	_____	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	4	Zhou et al., <u>Chem Pharm. Bull</u> 29 (10):2844-2850 (1981)
AS	4	Bomford, R., <u>Int. Archs Allergy Appl. Immun.</u> 63:127-131 (1982)
AT	4	Bomford, R., <u>Int. Archs Allergy appl. Immun.</u> 75:280-281 (1984)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

Atty Docket

0614.0690004

Serial No.

200,754

INFORMATION DISCLOSURE STATEMENT

Applicant

KENSIL, et al.

Filing Date

May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	_____	____/____/____	_____	_____	_____	_____
	AB	_____	____/____/____	_____	_____	_____	_____
	AC	_____	____/____/____	_____	_____	_____	_____
	AD	_____	____/____/____	_____	_____	_____	_____
	AE	_____	____/____/____	_____	_____	_____	_____
	AF	_____	____/____/____	_____	_____	_____	_____
	AG	_____	____/____/____	_____	_____	_____	_____
	AH	_____	____/____/____	_____	_____	_____	_____
	AI	_____	____/____/____	_____	_____	_____	_____
	AJ	_____	____/____/____	_____	_____	_____	_____
	AK	_____	____/____/____	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation
	AL	_____	____/____/____	_____	_____	_____	Yes No
	AM	_____	____/____/____	_____	_____	_____	Yes No
	AN	_____	____/____/____	_____	_____	_____	Yes No
	AO	_____	____/____/____	_____	_____	_____	Yes No
	AP	_____	____/____/____	_____	_____	_____	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Morein et al., <u>Nature</u> 308:457-460 (1984)
	AS	<u>5</u>	Strobbe et al., <u>Arch. Exper. Vet. Med.</u> 28:385-392 (1974)
	AT	<u>5</u>	Mostad and Doehl, <u>J. of Chromatography</u> 396:157-168 (1987)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

Atty Docket

0614.0690004

Serial No.

200,754

INFORMATION DISCLOSURE STATEMENT

Applicant

KENSIL, et al.

Filing Date

May 31, 1988

Group

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	/ /	/ /				
	AB	/ /	/ /				
	AC	/ /	/ /				
	AD	/ /	/ /				
	AE	/ /	/ /				
	AF	/ /	/ /				
	AG	/ /	/ /				
	AH	/ /	/ /				
	AI	/ /	/ /				
	AJ	/ /	/ /				
	AK	/ /	/ /				

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Trans-lation
	AL	/ /	/ /				Yes
	AM	/ /	/ /				No
	AN	/ /	/ /				Yes
	AO	/ /	/ /				No
	AP	/ /	/ /				Yes
							No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	6	Egerton et al., <u>Vet. Sci. Comm.</u> , 2:247-252 (1978)
AS	6	McColm et al., <u>Parasite Immun.</u> 4:337-347 (1982)

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.